Certara Introduces Certara.AI, the Life Sciences Specialized GPT Platform
Certara.AI Improves Drug Research & Development Processes with Secure, Client-Specific, A.I. Applications PRINCETON, N. J.—October…
CertaraOctober 5, 2023
Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model
Hugo Geerts, Silke Bergeler, Mike Walker, Piet van der Graaf, Jean-Philippe Courade. Sci Rep. 2023…
CertaraOctober 5, 2023
How Modeling Can Help to Improve Children’s Access to Properly Evaluated Medications
Regulatory guidance paves the way to address ethical concerns in pediatric trials, and how additional…
CertaraOctober 5, 2023
Clinical Pharmacology Issues That Can Lead to Approvability Problems for Your Drug
Clinical pharmacology information comprises more than 50% of a drug label. Inadequate clinical pharmacology development…
CertaraOctober 4, 2023
Certara Launches CoAuthor, a Regulatory and Medical Writing Tool
Using AI to gain efficiencies for medical writers PRINCETON, N. J.— October 3, 2023— Certara,…
CertaraOctober 3, 2023
Unlocking ROI through Omnichannel Stakeholder Engagement and Value Communication in Pharma
In a sector where both competition and stakeholder expectations are high, a comprehensive approach that…
CertaraOctober 2, 2023
Developing Pediatric PBPK Models for Differing Ethnic Populations
Physiologically-based pharmacokinetic (PBPK) modeling has proven invaluable in drug development, especially for pediatric populations, because…
CertaraSeptember 29, 2023
What recent paediatric guidelines mean for drug developers
Justin Hay, Senior Director, Amy Cheung Senior Director of Integrated Drug Development, and Patrick Loebs…
CertaraSeptember 25, 2023
